![](/images/graphics-bg.png)
Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
المؤلفون المشاركون
Johar, Asmah
Thevarajah, Suganthi
Heng, Agnes
Chan, Lee Chin
Ch’ng, Chin Chwen
Mohd Safdar, Najeeb Ahmad
Muniandy, Pubalan
Taib, Tarita
Tan, Wooi Chiang
Tey, Kwee Eng
المصدر
Dermatology Research and Practice
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-05-12
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Psoriasis is a chronic inflammatory skin disease affecting nearly 10% of dermatologic patients in Malaysia.
Treatment options include topical agents and phototherapy as well as nonbiologic and biologic systemic therapy.
Mild psoriasis can often be managed with topical agents.
However, managing moderate to severe psoriasis is more challenging and may require systemic treatment with nonbiologics or biologics.
Despite the availability of several biologics, there are many unmet clinical needs, which may be addressed by secukinumab, an IL-17A inhibitor.
This position statement is based on an expert panel discussion and is intended to provide dermatologists an overview of existing options as well as to provide a better understanding of secukinumab and how it can be integrated into current practice.
During the discussion, panel members examined current approaches and the role of secukinumab in plaque psoriasis management.
Panel members estimated that up to 30% of patients have moderate to severe psoriasis but only 1-2% receive biologics.
Highlights from the discussion were that (i) the threshold for biologic use should be lower, in line with international guidelines; (ii) studies have shown that secukinumab has several advantages over other biologics which are greater efficacy, sustained efficacy over time, rapid onset of action, and early evidence of possible disease-modifying potential; and (iii) ideal candidates for secukinumab are all patients of moderate to severe psoriasis, including those with history of treatment failure, difficult-to-treat patterns of psoriasis (nail, scalp, and palmoplantar psoriasis), psoriatic arthritis, and comorbidities and those aiming for clear skin.
Panel members recommend that secukinumab be considered first line option among biologic therapies.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Johar, Asmah& Thevarajah, Suganthi& Heng, Agnes& Chan, Lee Chin& Ch’ng, Chin Chwen& Mohd Safdar, Najeeb Ahmad…[et al.]. 2019. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective. Dermatology Research and Practice،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1148130
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Johar, Asmah…[et al.]. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective. Dermatology Research and Practice No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1148130
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Johar, Asmah& Thevarajah, Suganthi& Heng, Agnes& Chan, Lee Chin& Ch’ng, Chin Chwen& Mohd Safdar, Najeeb Ahmad…[et al.]. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective. Dermatology Research and Practice. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1148130
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1148130
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)